Skip to main content

Table 1 Main characteristics of studies included in the study

From: Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

Study, year Study design Type of HF Inclusion Criteria Exclusion Criteria Study comparison Type of statins Primary endpoints Follow-up
Horwich et al. 2004 Prospective cohort HFrEF HF patients EF > 40% Baseline incomplete data Statins: Control Not specified All-cause mortality; mortality mortality 12 mo
Sola et al. 2005 Prospective cohort HFrEF HF patients EF ≤35% NYHA II-III Prescribed statins > 1 year; intolerance to statins Statins: Control Atorvastatin Fluvastatin Pitavastatin Simvastatin All-cause mortality; Hospitalization 24 5 mo
Fukuta et al. 2005 Prospective cohort HFpEF HF patients EF < 50% Significant valvular disease; prosthetic valve Statins: Control Atorvastatin Simvastatin Pravastatin Fluvastatin All-cause mortality; Hospitalizations 21 ± 12 mo
Hong et al. 2005 Prospective cohort HFrEF HF patients < 40% HF patients with EF > 40% Statins: Control Simvastatin   12 mo
Go et al. 2006 Prospective cohort HFrEF HF patients   Statins: Control Not specified All-cause mortality; Hospitalizations 28 mo
Kjekshus et al. 2007 CORONA RCTs HFrEF HF patients, EF < 40%, NYHA II-IV previous statin- induced myopathy or hypersensitivity decompensated HF Statins: Control Rosuvastatin CV death Non-fatal MI Stroke 38.2 mo
Huan et al. 2007 Prospective cohort HFrEF HF patients with LVSD HF patients with LVDD Statins: Control Not specified All-cause mortality; 36 mo
Coleman et al. 2008 Prospective cohort HFrEF HF patients EF < 40%,und--ergoing ICD   Statins: Control Not specified All-cause Mortality VT/VF incidence 31 mo
Roik et al. 2008 Prospective cohort HFpEF HF patients with preserved EF LVEF ≤45%, ACS cardiogenic shock severe AS, etc. Statins: Control Simvastatin Atorvastatin All-cause mortality; Hospitalization 12 mo
Tevazzi et al. 2008 the GISSI-HF trial RCTs HFrEF HF patients NYHA II-IV Non-cardiac comorbidity (cancer) Statins: Control Rosuvastatin All-cause mortality; Hospitalization 3.9 y
Gomez-Soto et al. 2010 Prospective cohort HFpEF HF patients with preserved EF HF patients with reduced EF Statins: Control Not specified All-cause mortality; CV mortality Hospitalization 34.6 mo
Kaneko et al. 2013 Prospective cohort HFpEF HF patients with EF ≥50% Valvular heart disease EF < 50% Statins: Control Not specified CV mortality Hospitalization 3 y
Yap et al. 2015 Prospective cohort HFpEF HF patients with EF ≥50% Incomplete follow-up Non-documented EF Statins: Control Not specified All-cause mortality; 2 y
Nochioka et al. 2015 Prospective cohort HFpEF HF patients with stages B-D NR Statins: Control Not specified All-cause mortality; Hospitalization 3 y
Alehagen U et al. 2015 Prospective cohort HFpEF HF patients with EF ≥50% HF patients with EF < 50% Statins: Control Not specified All-cause mortality; 12 mo
Alehagen et al. 2015 Prospective cohort HFrEF HF patients HF patients with EF ≥50% Statins: Control Not specified All-cause mortality; 24 mo
Tsujimoto et al. 2018 Prospective cohort HFpEF HF patients with preserved EF HOCMP systemic illness with l Life expectancy < 3 y;    All-cause mortality; CV and Non-CV mortality; 3.3 y
  1. Abbreviations: HF: heart failure; HFrEF: heart failure with reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; CV: cardiovascular; ACS: acute coronary syndrome; AS: aortic stenosis; NR: non-reported; mo: months; y: years